Targeting G-quadruplex DNA As A Novel Therapeutic Strategy For Alzheimer’s And Frontotemporal Dementia
Funder
National Health and Medical Research Council
Funding Amount
$720,144.00
Summary
Dementia is the third leading cause of death in Australia and there is an urgent need to identify new ways of treating diseases that cause dementia. Our research is focused on targeting an unusual DNA structure in Alzheimer’s and Frontotemporal dementia (FTD). We will use a precision-targeted technology to better control formation of this DNA structure in disease-causing genes, allowing us to switch off the gene and hence stop disease progression for Alzheimer’s and FTD.
The Role Of The Neuronal Epigenome In Natural Brain Ageing And The Progression Of Alzheimer’s Disease
Funder
National Health and Medical Research Council
Funding Amount
$584,644.00
Summary
Most cases of Alzheimer's disease are sporadic or late onset, with only ~5% of cases being familial, suggesting a potential role for epigenetics. This project aims to profile the human brain epigenome throughout normal ageing and in Alzheimer's disease so we can determine how disturbed epigenetic states may affect brain function. This research will provide new insights into the role of the epigenome in Alzheimer's disease, enabling crucial advances in understanding its origins.
Neurodegenerative and neuromuscular diseases are difficult to diagnose and even more difficult to treat. They affect the elderly and children, usually at very early age, and often lead to premature death or chronic debilitation – they are usually incurable and 30-80% of patients remain undiagnosed. This program will identify new disease genes, establish routine diagnostics using cutting edge tools, identify novel and validate known biomarkers and develop novel treatment strategies.
Long-term Outcome Of Individuals Who Had A First-episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$1,344,905.00
Summary
The long-term illness course and outcomes of patients treated for first episode psychosis are poorly understood especially in terms of important domains such as social and vocational functioning, physical health, and quality of life. This treated cohort study of a sample of 786 patients, 15 years after their first episode of psychosis will be one of the longest and largest conducted to date. Results of the study will inform clinical practice and policy development.
The Effect Of Chronic Intermittent Alcohol Consumption On The Precipitation Of Dementia.
Funder
National Health and Medical Research Council
Funding Amount
$604,644.00
Summary
This proposal examines the relationship between chronic alcohol intake and alcohol-related dementia, and potential interventions for the treatment of alcohol related dementia.
PSYSCAN— Translating Neuroimaging Findings From Research Into Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$376,285.00
Summary
Our ability to predict the onset and outcome of schizophrenia and other psychotic disorders remains limited. This restricts the implementation of effective preventative and early interventions. This project will rectify this by developing a tool of significant clinical utility. The project has 2 aims: 1. To develop and validate a neuroimaging-based tool for use in early psychosis to assist with early diagnosis, outcome, and disease progression. 2. To apply the tool in clinical practice.
NOX Enzymes As Mediators Of Inflammation-triggered Neurodegeneration: Modulating NOX Enzymes As Novel Therapies
Funder
National Health and Medical Research Council
Funding Amount
$994,846.00
Summary
The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat ....The NEURINOX project aims at identifying novel therapeutic targets for neurodegenerative diseases; an increasing health issue for the ageing Australian population. NADPH oxidases (NOX) enzymes, generate reactive oxygen species, and are key regulators of neuroinflammation. Inflammatory dysregulation is characterized by a change in NOX activity. NEURINOX will expound the links between neuroinflammation, NOX enzyme activity & neurodegenerative diseases to identify novel therapeutic targets to treat neuroinflammation.Read moreRead less
Modifiable Risk Factors For Serious Mental Illness - An Integrated Program Of Epidemiology, Genetics And Clinical Trials
Funder
National Health and Medical Research Council
Funding Amount
$3,750,000.00
Summary
John McGrath has discovered that vitamin D during brain development is associated with psychosis. Just as the use of folate decreased the incidence of spina bifida, vitamin D supplementation could decrease the incidence of psychosis. Using international samples, McGrath will search for modifiable risk factors for mental illness related to nutrition, infection and stress. He will use the latest methods from genetics to explore modifiable risk factors and undertake clinical trials.
Personalised Prognostic Tools For Early Psychosis Management (PRONIA)
Funder
National Health and Medical Research Council
Funding Amount
$401,739.00
Summary
Psychosis can be a devastating illness with harmful long-term consequences, such as chronic schizophrenia. To avoid distress, deterioration, and potential disability, we need more accurate tools to personalise treatment for individuals by understanding their prognosis. The PRONIA project will help to improve methods of predicting outcomes by working with our European colleagues to create a cybernetic prognostic system for psychosis that uses brain imaging, genetics, cognition, and clinical marke ....Psychosis can be a devastating illness with harmful long-term consequences, such as chronic schizophrenia. To avoid distress, deterioration, and potential disability, we need more accurate tools to personalise treatment for individuals by understanding their prognosis. The PRONIA project will help to improve methods of predicting outcomes by working with our European colleagues to create a cybernetic prognostic system for psychosis that uses brain imaging, genetics, cognition, and clinical markers.Read moreRead less